Jazz Pharmaceuticals plc (J7Z) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Jazz Pharmaceuticals plc (J7Z) has a cash flow conversion efficiency ratio of 0.090x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€408.20 Million ≈ $477.23 Million USD) by net assets (€4.53 Billion ≈ $5.30 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See J7Z days of operational coverage to measure how many days the company can operate on defensive assets alone.
Jazz Pharmaceuticals plc - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Jazz Pharmaceuticals plc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Jazz Pharmaceuticals plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jazz Pharmaceuticals plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jefferies Financial Group Inc
NYSE:JEF
|
-0.097x |
|
Nantong Jianghai Capacitor Co Ltd
SHE:002484
|
0.075x |
|
Penske Automotive Group Inc
NYSE:PAG
|
0.038x |
|
Ecopro BM. Co. Ltd
KQ:247540
|
0.032x |
|
Trimble Inc
NASDAQ:TRMB
|
0.049x |
|
Dynatrace Holdings LLC
NYSE:DT
|
0.086x |
|
AVIC Jonhon Optronic Technology Co Ltd
SHE:002179
|
-0.036x |
|
Industrivarden AB ser. A
ST:INDU-A
|
0.045x |
Annual Cash Flow Conversion Efficiency for Jazz Pharmaceuticals plc (2013–2025)
The table below shows the annual cash flow conversion efficiency of Jazz Pharmaceuticals plc from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Jazz Pharmaceuticals plc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €4.32 Billion ≈ $5.05 Billion |
€1.36 Billion ≈ $1.59 Billion |
0.314x | -7.93% |
| 2024-12-31 | €4.09 Billion ≈ $4.79 Billion |
€1.40 Billion ≈ $1.63 Billion |
0.341x | +16.69% |
| 2023-12-31 | €3.74 Billion ≈ $4.37 Billion |
€1.09 Billion ≈ $1.28 Billion |
0.292x | -29.11% |
| 2022-12-31 | €3.09 Billion ≈ $3.61 Billion |
€1.27 Billion ≈ $1.49 Billion |
0.412x | +109.95% |
| 2021-12-31 | €3.97 Billion ≈ $4.64 Billion |
€778.51 Million ≈ $910.16 Million |
0.196x | -20.13% |
| 2020-12-31 | €3.66 Billion ≈ $4.28 Billion |
€899.65 Million ≈ $1.05 Billion |
0.246x | -1.50% |
| 2019-12-31 | €3.11 Billion ≈ $3.64 Billion |
€776.40 Million ≈ $907.69 Million |
0.250x | -13.86% |
| 2018-12-31 | €2.76 Billion ≈ $3.22 Billion |
€798.90 Million ≈ $934.00 Million |
0.290x | +13.41% |
| 2017-12-31 | €2.71 Billion ≈ $3.17 Billion |
€693.09 Million ≈ $810.29 Million |
0.255x | -19.04% |
| 2016-12-31 | €1.88 Billion ≈ $2.19 Billion |
€592.39 Million ≈ $692.57 Million |
0.316x | -5.17% |
| 2015-12-31 | €1.60 Billion ≈ $1.87 Billion |
€531.94 Million ≈ $621.90 Million |
0.333x | +11.94% |
| 2014-12-31 | €1.37 Billion ≈ $1.60 Billion |
€407.61 Million ≈ $476.53 Million |
0.297x | +33.52% |
| 2013-12-31 | €1.30 Billion ≈ $1.51 Billion |
€288.43 Million ≈ $337.21 Million |
0.223x | -- |
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC)… Read more